Media Thread, page-14984

LOS ALTOS, overnight.
RenovoRx (Nasdaq: RNXT), announced a publication of positive early-stage clinical data relating to RenovoRx’s Trans-Arterial Micro-Perfusion (TAMP) therapy platform in the international peer-reviewed journal, The Oncologist.
Data shows that chemotherapy delivered via TAMP with prior chemoradiation in Locally Advanced Pancreatic Cancer observed an Overall Survival of 27-months.
End.

In layman's terms, think of getting a ding in the car and rather than re-paint the entire vehicle the panel guy will mask outside the repaired area then touch up that part alone, that's what TAMP does, just treats the local tumor area not the entire body, with less side effects.

Imugene is waiting in the wings for its turn at delivering a range of their drugs via TAMP.,
Exciting stuff, rock on team.

All in my opinion & pure speculation.